ABSTRACTS from 16th International COnference on ... - CRRT Online

More documents

Recommendations

Info

<strong>ABSTRACTS</strong> FROM 17 TH INTERNATIONAL CONFERENCE ON CRRT, SAN DIEGO, FEB 14-17, 2012 Alexander Biro, Hananya Vaknine, Zipora Matas, Asora Fux, Leticia Schreiber, Mona Boaz, Zvi Burbea, Relu Cernes, Alexander Briliant, Ze'ev Katzir Nephrology Institute, E Wolfson Medical Center, Israel , Pathology Institute, E Wolfson Medical Center, Israel, Biochemistry Laboratory, E Wolfson Medial Center, Israel, Epidemiology Unit, E Wolfson Medical Center, Israel Background: Aminoglycosides cause nephrotoxicity in 1-2% of patients by generating reactive oxygen species (ROS), leading to DNA destruction and activation of poly(ADP-ribose) Polymerase (PARP). The ensuing decline in nicotinamide adenine dinucleotide (NAD) causes diminished cellular energetic capacity and necrotic tubular cell death. Methods: The effect of PARP inhibition on gentamicininduced nephrotoxicity was studied in 2 female Wistar-Kyoto rats divided into treatment groups: control (no treatment or PARP-inhibitor-treated [3-amino benzamine, 3AB]); gentamicin-treated; and gentamicin+3AB treated. Kidney function, protein and gentamicin levels and urinary trypsin inhibitory activity (TIA) were measured. Tissue microscopic examination and immunohistochemical study for Proliferative Cell Nuclear Antigen (PCNA) were determined. Results: The following results were obtained: Urea was 41.±5.8, 88.3±5.3 and 48.5±12.7 mg/dL in control, gentamicin and gentamicin+3AB-treated rats, respectively (p=.4). Proteinuria was 7.5±2.9 in controls, 41.2±18.1 in gentamicin-treated and 17.6±13.9 mg/24-hours in gentamicin+3AB-treated rats (p=.3). TIA was 528.75±357.9, 1365.±863.7 and 475.±194.4 inhibitory units/day in control, gentamicin and gentamicin+3AB-treated rats, respectively (p=.2). The number of macronuclei per 1mm2 was significantly higher in gentamicin-treated rats than in gentamicin+3AB treated rats (218±11.8 vs. 41.7±36.2. p=.4). The number of PCNA positive nuclei was marginally significantly higher in the gentamicintreated rats than in gentamicin+3AB treated rats (3585±2215.3 vs. to 626.7±236.9, p=.7). Conclusions: The effect of PARP inhibitor on the bactericidal activity of gentamicin was assessed, no effect was observed. This study illustrates that PARP inhibitor significantly attenuates gentamicin-induced nephrotoxicity in rats with no effect on its bactericidal activity. 33. Plasma NGAL Is An Early Biomarker Of Graft Function, Calcineurin Inhibitor Nephrotoxicity And Tubular Regeneration In Kidney Transplantation From Extended Criteria Donors Vincenzo Cantaluppi, Michela Tamagnone, Sergio Dellepiane, Davide Medica, Ana M Manzione, Maria Messina, Federico Figliolini, Luigi Biancone, Giovanni Camussi, Giuseppe P Segoloni University of Turin, San Giovanni Battista Molinette Hospital Background: Delayed graft function (DGF), defined as the need for dialysis in the first week after kidney transplantation (KT), has been increasing for the use of kidneys <strong>from</strong> extended criteria donors (ECD). Plasma Neutrophil Gelatinase-Associated Lipocalin-2 (NGAL) has been proposed as early biomarker of DGF. Aims: The aims of this study were to evaluate: 1) NGAL in 5 patients in the first 24h after 147
<strong>ABSTRACTS</strong> FROM 17 TH INTERNATIONAL CONFERENCE ON CRRT, SAN DIEGO, FEB 14-17, 2012 KT <strong>from</strong> ECD; 2) the relationship between NGAL and DGF, slow graft function (SGF) and immediate graft function (IGF); 3) the trend of serum creatinine (sCr) and plasma NGAL in the first 5 days after KT; 4) NGAL before and after the introduction of calcineurin inhibitors (CNI); 5) the in vitro role of NGAL in tubular regeneration. Methods: Fifty patients were enrolled in the study (immunosuppression with basiliximab, MMF and steroids: CNI introduced when sCr 3 mg% at day 6 after KT) and IGF (sCr
Page 2 and 3:
CRRT 2012 SEVENTEENTH INTERNATIONAL
Page 4 and 5:
FACULTY DISCLOSURES CRRT 2012 Facul
Page 6 and 7:
CRRT 2012 ORGANIZING COMMITTEE USA
Page 8 and 9:
CRRT 2012 FACULTY Patrick Honoré,
Page 10 and 11:
ACKNOWLEDGEMENTS CRRT 2012 ACKNOWLE
Page 12 and 13:
PLENARY SESSIONS CRRT 2012 PROGRAM/
Page 14 and 15:
Page 16 and 17:
Page 18 and 19:
WORKSHOPS CRRT 2012 PROGRAM/INDEX T
Page 20 and 21:
WORKSHOPS CRRT 2012 PROGRAM/INDEX W
Page 22 and 23:
POSTER ABSTRACTS C
Page 24 and 25:
POSTER ABSTRACTS C
Page 26 and 27:
NURSING FORUM LUNCHEON Communicatio
Page 28 and 29:
Nutritional Support in ICU Patients
Page 30 and 31:
Educational Objectives: The Endothe
Page 32 and 33:
SPECIAL LECTURE Engineering Critica
Page 34 and 35:
Nishimura R, Ornato JP, Page RL, Ri
Page 36 and 37:
Do Vasoactive Drugs and Fluids Impr
Page 38 and 39:
Blood Transfusions are Important fo
Page 40 and 41:
Thinking Outside of the Box: A Nove
Page 42 and 43:
Nursing Forum 2 Luncheon Benchmarki
Page 44 and 45:
4. Mori K, Lee HT, Rapoport D, Drex
Page 46 and 47:
Differential Diagnosis of AKI: Can
Page 48 and 49:
Myocardial Stunning and Brain Edema
Page 50 and 51:
4. Udy A, Roberts JA, Lipman J. Wha
Page 52 and 53:
CRRT and ECMO: Techniques and Outco
Page 54 and 55:
Management of Severe Heart Failure:
Page 56 and 57:
Avoiding Anticoagulation for CRRT:
Page 58 and 59:
Improving Outcomes from</st
Page 60 and 61:
The Changing Face of AKI: Snapshots
Page 62 and 63:
Alkaline Phosphatase Peter Pickkers
Page 64 and 65:
creatinine (Cr) was measured using
Page 66 and 67:
Surveillance and Early Recognition
Page 68 and 69:
therapy admitted to general intensi
Page 70 and 71:
A01 Assessing the Microcirculation
Page 72 and 73:
A01 Assessing the Microcirculation
Page 74 and 75:
C03 Critical Care Pharmacology: Vas
Page 76 and 77:
D04 Biomarkers 1: Principles and Ap
Page 78 and 79:
6. Ferguson JW, Dover AR, Chia S, C
Page 80 and 81:
G07 Fluids and Solutions in the Cri
Page 82 and 83:
A09 Vascular Access /Membrane and C
Page 84 and 85:
A09 Vascular Access /Membrane and C
Page 86 and 87:
C11 Critical Care Management: Nutri
Page 88 and 89:
D12 Biomarkers 2: Application in AK
Page 90 and 91:
Educational Objectives: E13 Liver a
Page 92 and 93:
G15 Fluids and Solutions in the Cri
Page 94 and 95:
Educational Objectives: 1) Discuss
Page 96 and 97:
B18 Fluid Management Ravindra L. Me
Page 98 and 99: C19 Acid Base and Electrolyte Probl
Page 100 and 101: D20 Extracorporeal Techniques for S
Page 102 and 103: the mediatordelivery hypothesis. In
Page 104 and 105: F22 Ensuring Patient Safety and Qua
Page 106 and 107: H24 Patient Centered Care in the IC
Page 108 and 109: B26 Starting and Stopping RRT for A
Page 110 and 111: C27 Acid Base and Electrolyte Probl
Page 112 and 113: D28 Extracorporeal Techniques for S
Page 114 and 115: E29 Heart Failure and Cardio-Renal
Page 116 and 117: F30 Ensuring Patient Safety and Qua
Page 118 and 119: H32 Withdrawing & Withholding Suppo
Page 120 and 121: Patel SS, Holley JL. Withholding an
Page 122 and 123: ABSTRACTS FROM 17
show all

ABSTRACTS from 16th International COnference on ... - CRRT Online

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?